Novel combinations of long-acting β2-agonists and long-acting antimuscarinic agents undergoing development
| Drug(s) | Advantages | Latest developments | Company working on this strategy |
| Indacaterol/glycopyrronium bromide (QVA-149) | No data presented yet. | Phase II/III | Novartis, Basle, Switzerland |
| BI-1744-CL/tiotropium | No data presented yet. | Phase II | Boehringer Ingelheim, Ingelheim, Germany |
| Aclidinium/formoterol (LAS-40464) | No data presented yet. It should be established whether formoterol can be administered on a once-daily basis. | Phase II | Almirall Prodesfarma, Barcelona, Spain |
| Milveterol or GSK-642444/ darotropium bromide | No data presented yet. | Phase I/II | GlaxoSmithKline, London, UK |
| Carmoterol/tiotropium | No data presented yet. | Phase I/II | Chiesi Farmaceutici, Parma, Italy |
| Formoterol/dexpirronium | No data presented yet. It should be established whether formoterol can be administered on a once-daily basis. | Phase I/II? | Meda Pharma, Bad Homburg, Germany |
| GSK-961081 | It is both a muscarinic antagonist and a β2-adrenoceptor agonist. It is at least equivalent to 50 μg salmeterol b.i.d. plus 18 μg tiotropium u.i.d. | Phase II | GlaxoSmithKline, London, UK/Theravance, South San Francisco, CA, USA |